Amgen
AMGN | NASDAQ
$462.32
-$3.35 (-0.72%)
At close: Nov 16, 2026, 4:00 PM ET
$463.98
+$1.66 (+0.36%)
After-hours:
Nov 16, 2026, 7:55 PM ET
Amgen Company Profile
Company profile explainedCompany Profile
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Key Executives
| Name | Position |
|---|---|
| Robert A. Bradway | Chairman & CEO |
| Scott Skellenger | Senior Vice President & Chief Information Officer |
| Sean Bruich | SVP & Chief Technology Officer |
| Thomas J. W. Dittrich | Executive Vice President & Chief Financial Officer |
| Casey Capparelli | Executive Director of Investor Relations |
| Esteban Santos | Executive Vice President of Operations |
| Howard Y. Chang | Senior Vice President of Global Research & Chief Scientific Officer |
| James E. Bradner | EVP of Research & Development, Artificial Intelligence and Data |
| Jonathan Graham | Executive Vice President, General Counsel & Secretary |
| Matthew C. Busch | Chief Accounting Officer & Vice President of Finance |
| Murdo Gordon | Executive Vice President of Global Markets and Policy |
| Peter H. Griffith | Executive Vice President |
Amgen
| Country | United States |
| IPO Date | Jun 17, 1983 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 31,500 |
| CEO | Robert A. Bradway |
Contact Details
One Amgen Center Drive Thousand Oaks,
California 91320-1799 United States
Stock Details
| Ticker Symbol | AMGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318154 |
| CUSIP Number | 031162100 |
| ISIN Number | US0311621009 |
| SIC Code | 2836 |
Recent News
- 1 day ago / 247wallst.com4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week Ahead
- 3 days ago / fool.comAmgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
- 5 days ago / benzinga.comAmgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
- 5 days ago / 247wallst.comWant $7,000 in Passive Income? Buy These 3 Dividend Stocks Today
- 5 days ago / reuters.comAmgen's experimental Sjogren's drug meets late-stage trial goal
- 5 days ago / prnewswire.comAMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
- 6 days ago / 247wallst.comAmgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?
- 6 days ago / 247wallst.com3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
- 7 days ago / prnewswire.comNEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
- 8 days ago / zacks.comHere is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Add to Watchlist
Select watchlists to add or remove AMGN